Target intelligence / Profile preview

Intestinal mucosal barrier components (IMB)

Target
IMB
Molecular classification
Other, Cell adhesion molecule, Secreted protein, Immune system component
01

Overview

The intestinal mucosal barrier is a multi-component system that serves as the primary interface between the host and the external environment of the gut lumen. It consists of a physical barrier formed by a single layer of intestinal epithelial cells connected by tight junction proteins (such as claudins and occludin), a chemical barrier comprising a thick mucus layer and antimicrobial peptides, and an immunological barrier involving secretory IgA and specialized immune cells (Vancamelbeke & Vermeire, 2017, PMID: 28650209). Its fundamental biological function is to selectively allow the absorption of nutrients, water, and electrolytes while preventing the translocation of harmful pathogens, toxins, and dietary antigens into the systemic circulation (Okumura & Takeda, 2017, PMID: 28546564). Dysfunction of this barrier, often characterized by increased permeability or "leaky gut," is a central feature in the pathogenesis of inflammatory bowel disease (IBD), celiac disease, and various metabolic disorders (Groschwitz & Hogan, 2009, PMID: 19560575). Therapeutic interventions targeting these components include tight junction regulators like larazotide acetate, which aims to restore barrier integrity, and mucosal protectants or growth factors like teduglutide that promote epithelial repair.

Other names
Gut barrierIntestinal epithelial barrierMucosal barrierIntestinal lining
02

Mechanism of action

Modulation of tight junction permeability, stimulation of mucus secretion, enhancement of epithelial cell proliferation, and regulation of mucosal immune responses.

03

Biological functions

Immune responseNutrient absorptionPathogen exclusionHomeostasisCell-cell adhesion
04

Disease associations

InflammationInfectionAutoimmune diseaseMetabolic diseaseCancer
05

Safety considerations

Risk of systemic endotoxemia if barrier is compromisedPotential for malabsorptionAlteration of gut microbiome balanceImmunogenicity of biological agents
06

Interacting drugs

Larazotide

4 more in the full profile.

07

Biomarkers

ZonulinFecal calprotectinCitrullineLactulose-to-mannitol ratioIntestinal fatty acid-binding protein (I-FABP)

Beyond the preview

Go deeper on Intestinal mucosal barrier components (IMB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal mucosal barrier components (IMB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call